Long GV, et al. - In a single-arm, open-label, single-center, phase 2 study (NeoCombi) run at Melanoma Institute Australia (Sydney, NSW, Australia), researchers examined patients with resectable clinical stage III melanoma who were treated with neoadjuvant dabrafenib plus trametinib therapy to determine the proportion of patients who would have a pathological response and a response according to Response Evaluation Criteria in Solid Tumors (RECIST). In this study with 35 eligible patients, neoadjuvant dabrafenib plus trametinib therapy resulted in a complete response according to RECIST as well as a complete pathological response in a high proportion of patients, with no progression during neoadjuvant therapy, and therefore, may deserve a place in the management of RECIST-measurable resectable stage III melanoma. All 35 patients achieved a pathological response following resection and pathological evaluation, of whom 49% had a complete pathological response and 51% had a non-complete pathological response.